» Articles » PMID: 11042569

The Effect of Less Than Definitive Care on Breast Carcinoma Recurrence and Mortality

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2000 Oct 24
PMID 11042569
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Risk factors for breast carcinoma offer few opportunities for prevention; thus, the reduction of morbidity and mortality among breast carcinoma patients must remain a priority. The objective of this study was to measure the effects of less than definitive care for patients with breast carcinoma on disease recurrence and mortality.

Methods: The prognostic evaluation and treatment received by an inception cohort of 494 women was characterized. Three hundred ninety women ages 45-90 years with local or regional breast carcinoma who were diagnosed between 1984 and 1986 and were treated at one of eight Rhode Island hospitals comprised the final cohort. Disease recurrence and mortality were ascertained through December 31, 1996. Candidate determinants of outcomes were a less than definitive prognostic evaluation and less than definitive primary therapy-adjusted for confounding by patient age, extent of disease, and comorbid diseases.

Results: During the first 5 years of follow-up, patients who received a less than definitive prognostic evaluation had an adjusted relative hazard of recurrence of 1.7 (95% confidence interval, 1.0-2.7) and an adjusted relative hazard for breast carcinoma mortality of 2.2 (95% confidence interval, 1.2-3.9). Patients who received less than definitive therapy had an adjusted relative hazard of recurrence of 1.6 (95% confidence interval, 1.0-2.5), and an adjusted relative hazard of breast carcinoma mortality of 1.7 (95% confidence interval, 1.0-2.8).

Conclusions: Breast carcinoma patients who receive less than definitive care are at excess risk for disease recurrence and mortality. Women with early stage breast carcinoma should be treated in accordance with existing guidelines.

Citing Articles

G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits.

Azam S, Haque M, Jakaria M, Jo S, Kim I, Choi D Cells. 2020; 9(2).

PMID: 32102186 PMC: 7072884. DOI: 10.3390/cells9020506.


The age-adjusted Charlson comorbidity index as a predictor of survival in surgically treated vulvar cancer patients.

Di Donato V, Page Z, Bracchi C, Tomao F, Musella A, Perniola G J Gynecol Oncol. 2018; 30(1):e6.

PMID: 30479090 PMC: 6304403. DOI: 10.3802/jgo.2019.30.e6.


Variations in Guideline-Concordant Breast Cancer Adjuvant Therapy in Rural Georgia.

Guy Jr G, Lipscomb J, Gillespie T, Goodman M, Richardson L, Ward K Health Serv Res. 2014; 50(4):1088-108.

PMID: 25491350 PMC: 4545348. DOI: 10.1111/1475-6773.12269.


Comorbid diseases interact with breast cancer to affect mortality in the first year after diagnosis--a Danish nationwide matched cohort study.

Ording A, Garne J, Nystrom P, Froslev T, Sorensen H, Lash T PLoS One. 2013; 8(10):e76013.

PMID: 24130755 PMC: 3794020. DOI: 10.1371/journal.pone.0076013.


Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer.

Friese C, Pini T, Li Y, Abrahamse P, Graff J, Hamilton A Breast Cancer Res Treat. 2013; 138(3):931-9.

PMID: 23542957 PMC: 3633703. DOI: 10.1007/s10549-013-2499-9.